You have access
Phase II Trial of Erlotinib plus Capecitabine as First-line Treatment for Metastatic Pancreatic Cancer (XELTA Study)
RAFAEL LÓPEZ, CARLOS MÉNDEZ MÉNDEZ, MÓNICA JORGE FERNÁNDEZ, CARLOS ROMERO REINOSO, GUILLERMO QUINTERO ALDANA, MERCEDES SALGADO FERNÁNDEZ, JUAN DE LA CÁMARA GÓMEZ, MARGARITA REBOREDO LÓPEZ, MANUEL RAMOS VÁZQUEZ and SONIA CANDAMIO FOLGAR
Anticancer Research February 2013, 33 (2) 717-723;